Results 21 to 30 of about 4,569 (190)

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2021
BackgroundRadium-223 improves overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (mCRPC). While the exact mechanism behind this survival benefit remains unclear, radium-induced immunological mechanisms might contribute
Jeroen H. A. Creemers, Jeroen H. A. Creemers, Maarten J. van der Doelen, Maarten J. van der Doelen, Sandra van Wilpe, Sandra van Wilpe, Rick Hermsen, Tjitske Duiveman-de Boer, Diederik M. Somford, Marcel J. R. Janssen, J. P. Michiel Sedelaar, Niven Mehra, Niven Mehra, Johannes Textor, Johannes Textor, Harm Westdorp, Harm Westdorp   +16 more
doaj   +1 more source

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)

BMC Cancer, 2020
Background Metastasis directed therapy (MDT) for patients with oligometastatic disease is associated with improvements in progression free survival (PFS) and overall survival (OS) compared to systemic therapy alone. Additionally, within a prostate-cancer-
Hamza Hasan, Matthew P. Deek, Ryan Phillips, Robert F. Hobbs, Reem Malek, Noura Radwan, Ana P. Kiess, Shirl Dipasquale, James Huang, Terry Caldwell, Jessica Leitzel, Danielle Wendler, Hao Wang, Elizabeth Thompson, Jonathan Powell, Sara Dudley, Curtiland Deville, Stephen C. Greco, Daniel Y. Song, Theodore L. DeWeese, Michael A. Gorin, Steven P. Rowe, Sam Denmeade, Mark Markowski, Emmanuel S. Antonarakis, Michael A. Carducci, Mario A. Eisenberger, Martin G. Pomper, Kenneth J. Pienta, Channing J. Paller, Phuoc T. Tran   +30 more
doaj   +1 more source

A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

PLoS ONE, 2021
IntroductionRadium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival as monotherapy in patients with metastatic castration-resistant prostate cancer.
Stephanie I Kim, Andy H Szeto, Katherine P Morgan, Blaine Brower, Mary W Dunn, Amir H Khandani, Paul A Godley, Tracy L Rose, Ethan M Basch, Matthew I Milowsky, Young E Whang, Daniel J Crona   +11 more
doaj   +1 more source

Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience

Prostate International, 2019
Background: Treatment with radium-223 has been shown to increase survival and to delay skeletal events related to bone metastases of patients with metastatic Castration Resistant Prostate Cancer (mCRPC).
Renato P. Costa, Sebastiano Bordonaro, Francesco Cappuccio, Vincenzo Tripoli, Alessandra Murabito, Maria Licari, Maria R. Valerio, Paolo Tralongo   +7 more
doaj   +1 more source

Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study

Therapeutic Advances in Medical Oncology, 2021
Background: Radium-223 and enzalutamide are approved agents for patients with metastatic castration-resistant prostate cancer (mCRPC). Combining radium-223 and enzalutamide to improve outcomes is of clinical interest due to their differing modes of ...
Raymond S. McDermott, John Greene, John McCaffrey, Imelda Parker, Sylva Helanova, Anne-Marie Baird, Ausra Teiserskiene, Marvin Lim, Helen Matthews, Olwyn Deignan, John Feeney, Pierre G. Thirion, Stephen P. Finn, Paul J. Kelly   +13 more
doaj   +1 more source

Navigating the mCRPC Landscape: Exploring Key Clinical Decision Points [PDF]

European Medical Journal Urology, 2015
The Bayer satellite symposium was introduced by Prof Fred Saad, who gave an introduction into the use of radium-223 in metastatic castration-resistant prostate cancer (mCRPC).
Fred Saad, Gero Kramer, Bertrand Tombal, Jürgen Gschwend   +3 more
doaj  

Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases

World Journal of Nuclear Medicine, 2021
A retrospective analysis was performed of epidemiological data assessing the survival of patients who had received radium-223 for castrate-resistant metastatic prostate cancer treated at a regional tertiary referral center over a 5-year period.
John Buscombe, Daniel Gillett, Nick Bird, Anne Powell, Sarah Heard, Luigi Aloj   +5 more
doaj   +1 more source

Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain

Journal of Health Economics and Outcomes Research, 2018
# Purpose To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain.
Eva Tirado Mercier, Daniel Callejo Velasco, Marta Rubio Cabezas, Cristina Moretones Agut, Meritxell Granell Villalón   +4 more
doaj   +1 more source

Radium-223 in metastatic castration resistant prostate cancer

Asian Journal of Andrology, 2014
In 2004, docetaxel was approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). For the next several years, there was a lull in drug approvals.
Winston Vuong, Oliver Sartor, Sumanta K Pal   +2 more
doaj   +1 more source

Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges

World Journal of Nuclear Medicine, 2022
Aim Radium-223 has been the first-approved targeted Alpha therapy agent. We retrospectively assessed different factors influencing the overall survival (OS) and patient management.
Amit Bhoil, Phei Shan Chuah, Nagabhushan Seshadri, Sobhan Vinjamuri   +3 more
doaj   +1 more source